{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:50:59Z","timestamp":1791449459402,"version":"4.3.3"},"reference-count":280,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"DOI":"10.1038\/s41571-026-01211-5","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:02:15Z","timestamp":1791446535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-0228","authenticated-orcid":false,"given":"Paolo","family":"Tarantino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Valenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Segui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-540X","authenticated-orcid":false,"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne G.","family":"Waks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"1211_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182 (1987).","journal-title":"Science"},{"key":"1211_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783\u2013792 https:\/\/doi.org\/10.1056\/NEJM200103153441101 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino, P. et al. Antibody\u2013drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J. Clin. 72, 165\u2013182 https:\/\/doi.org\/10.3322\/caac.21705 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"1211_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","author":"N Howlader","year":"2014","unstructured":"Howlader, N. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J. Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/dju055 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"1211_CR5","doi-asserted-by":"publisher","first-page":"e0184680","DOI":"10.1371\/journal.pone.0184680","volume":"12","author":"OC Buonomo","year":"2017","unstructured":"Buonomo, O. C. et al. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. PLoS ONE 12, e0184680 https:\/\/doi.org\/10.1371\/journal.pone.0184680 (2017).","journal-title":"PLoS ONE"},{"key":"1211_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101\u2013126 https:\/\/doi.org\/10.1038\/s41573-022-00579-0 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1211_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100114","volume":"6","author":"T Grinda","year":"2021","unstructured":"Grinda, T. et al. Evolution of overall survival and receipt of new therapies by subtype among 20\u2009446 metastatic breast cancer patients in the 2008-2017 ESME cohort. ESMO Open 6, 100114 https:\/\/doi.org\/10.1016\/j.esmoop.2021.100114 (2021).","journal-title":"ESMO Open"},{"key":"1211_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_100023","author":"D File","year":"2020","unstructured":"File, D., Curigliano, G. & Carey, L. A. Escalating and de-escalating therapy for early-stage HER2-positive breast cancer. Am. Soc. Clin. Oncol. Educ. Book https:\/\/doi.org\/10.1200\/edbk_100023 (2020).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1211_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJMoa2508668","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney, S. M. et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. N. Engl. J. Med. 394, 551\u2013562 https:\/\/doi.org\/10.1056\/NEJMoa2508668 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR10","doi-asserted-by":"publisher","first-page":"GS1-01","DOI":"10.1158\/1557-3265.Sabcs25-gs1-01","volume":"32","author":"E Hamilton","year":"2026","unstructured":"Hamilton, E. et al. Abstract GS1-01: HER2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer. Clin. Cancer Res. 32, GS1-01 https:\/\/doi.org\/10.1158\/1557-3265.Sabcs25-gs1-01 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJMoa2514661","volume":"394","author":"S Loibl","year":"2026","unstructured":"Loibl, S. et al. Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N. Engl. J. Med. 394, 845\u2013857 https:\/\/doi.org\/10.1056\/NEJMoa2514661 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","volume":"37","author":"N Harbeck","year":"2026","unstructured":"Harbeck, N. et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Ann. Oncol. 37, 166\u2013179 https:\/\/doi.org\/10.1016\/j.annonc.2025.10.019 (2026).","journal-title":"Ann. Oncol."},{"key":"1211_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1056\/NEJMoa2511218","volume":"394","author":"O Metzger","year":"2026","unstructured":"Metzger, O. et al. Palbociclib for hormone-receptor\u2013positive, HER2-positive advanced breast cancer. N. Engl. J. Med. 394, 451\u2013462 https:\/\/doi.org\/10.1056\/NEJMoa2511218 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jamaoncol.2021.6597","volume":"8","author":"P Tarantino","year":"2022","unstructured":"Tarantino, P. et al. Aiming at a tailored cure for ERBB2-positive metastatic breast cancer: a review. JAMA Oncol. 8, 629\u2013635 https:\/\/doi.org\/10.1001\/jamaoncol.2021.6597 (2022).","journal-title":"JAMA Oncol."},{"key":"1211_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0959-8049(01)00230-1","volume":"37","author":"Y Yarden","year":"2001","unstructured":"Yarden, Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37, 3\u20138 https:\/\/doi.org\/10.1016\/S0959-8049(01)00230-1 (2001).","journal-title":"Eur. J. Cancer"},{"key":"1211_CR16","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","volume":"26","author":"MM Moasser","year":"2007","unstructured":"Moasser, M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469\u20136487 https:\/\/doi.org\/10.1038\/sj.onc.1210477 (2007).","journal-title":"Oncogene"},{"key":"1211_CR17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon, D. J. et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707\u2013712 (1989).","journal-title":"Science"},{"key":"1211_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nri2763","volume":"10","author":"O Leavy","year":"2010","unstructured":"Leavy, O. Therapeutic antibodies: past, present and future. Nat. Rev. Immunol. 10, 297 https:\/\/doi.org\/10.1038\/nri2763 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1211_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3069","volume":"13","author":"JL Nordstrom","year":"2011","unstructured":"Nordstrom, J. L. et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc\u03b3 receptor binding properties. Breast Cancer Res. 13, R123 https:\/\/doi.org\/10.1186\/bcr3069 (2011).","journal-title":"Breast Cancer Res."},{"key":"1211_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/s1535-6108(02)00097-1","volume":"2","author":"DB Agus","year":"2002","unstructured":"Agus, D. B. et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2, 127\u2013137 https:\/\/doi.org\/10.1016\/s1535-6108(02)00097-1 (2002).","journal-title":"Cancer Cell"},{"key":"1211_CR21","first-page":"2825","volume":"58","author":"J Baselga","year":"1998","unstructured":"Baselga, J., Norton, L., Albanell, J., Kim, Y. M. & Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825\u20132831 (1998).","journal-title":"Cancer Res."},{"key":"1211_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ph14090884","author":"G Antonarelli","year":"2021","unstructured":"Antonarelli, G. et al. Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies. Pharmaceuticals https:\/\/doi.org\/10.3390\/ph14090884 (2021).","journal-title":"Pharmaceuticals"},{"key":"1211_CR23","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","volume":"23","author":"SL Moulder","year":"2017","unstructured":"Moulder, S. L. et al. Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2+-advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer (MBC). Clin. Cancer Res. 23, 3529\u20133536 https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1496 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR24","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/0008-5472.Can-03-2868","volume":"64","author":"SK Rabindran","year":"2004","unstructured":"Rabindran, S. K. et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64, 3958\u20133965 https:\/\/doi.org\/10.1158\/0008-5472.Can-03-2868 (2004).","journal-title":"Cancer Res."},{"key":"1211_CR25","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","volume":"21","author":"W Xia","year":"2002","unstructured":"Xia, W. et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/erbB2 and downstream Erk1\/2 and AKT pathways. Oncogene 21, 6255\u20136263 https:\/\/doi.org\/10.1038\/sj.onc.1205794 (2002).","journal-title":"Oncogene"},{"key":"1211_CR26","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M. & de Vries, E. G. E. The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov. 14, 2089\u20132108 https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0708 (2024).","journal-title":"Cancer Discov."},{"key":"1211_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380, 617\u2013628 https:\/\/doi.org\/10.1056\/NEJMoa1814017 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR28","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783\u20131791 https:\/\/doi.org\/10.1056\/NEJMoa1209124 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR29","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2009.26.2071","volume":"28","author":"IE Krop","year":"2010","unstructured":"Krop, I. E. et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28, 2698\u20132704 https:\/\/doi.org\/10.1200\/JCO.2009.26.2071 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med. 382, 610\u2013621 https:\/\/doi.org\/10.1056\/NEJMoa1914510 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR31","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","volume":"18","author":"T Doi","year":"2017","unstructured":"Doi, T. et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 18, 1512\u20131522 https:\/\/doi.org\/10.1016\/S1470-2045(17)30604-6 (2017).","journal-title":"Lancet Oncol."},{"key":"1211_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","volume":"59","author":"F Schettini","year":"2021","unstructured":"Schettini, F. & Prat, A. Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast 59, 339\u2013350 https:\/\/doi.org\/10.1016\/j.breast.2021.07.019 (2021).","journal-title":"Breast"},{"key":"1211_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/jnci\/djz042","volume":"112","author":"A Prat","year":"2020","unstructured":"Prat, A. et al. HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. J. Natl Cancer Inst. 112, 46\u201354 https:\/\/doi.org\/10.1093\/jnci\/djz042 (2020).","journal-title":"J. Natl Cancer Inst."},{"key":"1211_CR34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000354253","volume":"8","author":"M Giuliano","year":"2013","unstructured":"Giuliano, M., Trivedi, M. V. & Schiff, R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care 8, 256\u2013262 https:\/\/doi.org\/10.1159\/000354253 (2013).","journal-title":"Breast Care"},{"key":"1211_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12222","volume":"7","author":"A Ferrari","year":"2016","unstructured":"Ferrari, A. et al. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nat. Commun. 7, 12222 https:\/\/doi.org\/10.1038\/ncomms12222 (2016).","journal-title":"Nat. Commun."},{"key":"1211_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju152","author":"A Prat","year":"2014","unstructured":"Prat, A. et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J. Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/dju152 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"1211_CR37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamaoncol.2022.6288","volume":"9","author":"A Fernandez-Martinez","year":"2023","unstructured":"Fernandez-Martinez, A. et al. Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2\/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials. JAMA Oncol. 9, 490\u2013499 https:\/\/doi.org\/10.1001\/jamaoncol.2022.6288 (2023).","journal-title":"JAMA Oncol."},{"key":"1211_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00533-2","volume":"9","author":"M Pegram","year":"2023","unstructured":"Pegram, M., Jackisch, C. & Johnston, S. R. D. Estrogen\/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer. npj Breast Cancer 9, 45 https:\/\/doi.org\/10.1038\/s41523-023-00533-2 (2023).","journal-title":"npj Breast Cancer"},{"key":"1211_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3067","volume":"13","author":"YC Wang","year":"2011","unstructured":"Wang, Y. C. et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers\u2013role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 13, R121 https:\/\/doi.org\/10.1186\/bcr3067 (2011).","journal-title":"Breast Cancer Res."},{"key":"1211_CR40","doi-asserted-by":"publisher","first-page":"v603","DOI":"10.1093\/annonc\/mdx391.026","volume":"28","author":"JM Cejalvo","year":"2017","unstructured":"Cejalvo, J. M. et al. Distribution of the PAM50 breast cancer subtypes within each pathology-based group: a combined analysis of 15,339 patients across 29 studies. Ann. Oncol. 28, v603 https:\/\/doi.org\/10.1093\/annonc\/mdx391.026 (2017).","journal-title":"Ann. Oncol."},{"key":"1211_CR41","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1158\/1078-0432.CCR-19-2612","volume":"26","author":"M Brandao","year":"2020","unstructured":"Brandao, M. et al. What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer? Clin. Cancer Res. 26, 2783\u20132788 https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2612 (2020)","journal-title":"Clin. Cancer Res."},{"key":"1211_CR42","doi-asserted-by":"publisher","unstructured":"The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 https:\/\/doi.org\/10.1038\/nature11412 (2012).","DOI":"10.1038\/nature11412"},{"key":"1211_CR43","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","volume":"11","author":"OM Filho","year":"2021","unstructured":"Filho, O. M. et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov. 11, 2474\u20132487 https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1557 (2021).","journal-title":"Cancer Discov."},{"key":"1211_CR44","doi-asserted-by":"publisher","first-page":"611","DOI":"10.5858\/133.4.611","volume":"133","author":"GH Vance","year":"2009","unstructured":"Vance, G. H. et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch. Pathol. Lab. Med. 133, 611\u2013612 https:\/\/doi.org\/10.5858\/133.4.611 (2009).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1211_CR45","doi-asserted-by":"publisher","unstructured":"Metzger, O. et al. Abstract PS09-02: event-free survival by residual cancer burden (RCB) and intratumor HER2 heterogeneity after neoadjuvant T-DM1 and pertuzumab for early-stage HER2-positive breast cancer. Cancer Res. 84 (9_suppl.), PS09-02 https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-PS09-02 (2024).","DOI":"10.1158\/1538-7445.SABCS23-PS09-02"},{"key":"1211_CR46","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/annonc\/mdw197","volume":"27","author":"S Loibl","year":"2016","unstructured":"Loibl, S. et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann. Oncol. 27, 1519\u20131525 https:\/\/doi.org\/10.1093\/annonc\/mdw197 (2016).","journal-title":"Ann. Oncol."},{"key":"1211_CR47","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/JCO.2013.54.5384","volume":"32","author":"J Baselga","year":"2014","unstructured":"Baselga, J. et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J. Clin. Oncol. 32, 3753\u20133761 https:\/\/doi.org\/10.1200\/JCO.2013.54.5384 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","volume":"29","author":"S Goel","year":"2016","unstructured":"Goel, S. et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors. Cancer Cell 29, 255\u2013269 https:\/\/doi.org\/10.1016\/j.ccell.2016.02.006 (2016).","journal-title":"Cancer Cell"},{"key":"1211_CR49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ccell.2016.02.016","volume":"29","author":"M Malumbres","year":"2016","unstructured":"Malumbres, M. CDK4\/6 inhibitors resTORe therapeutic sensitivity in HER2+ breast cancer. Cancer Cell 29, 243\u2013244 https:\/\/doi.org\/10.1016\/j.ccell.2016.02.016 (2016).","journal-title":"Cancer Cell"},{"key":"1211_CR50","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","volume":"1","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 1, 448\u2013454 https:\/\/doi.org\/10.1001\/jamaoncol.2015.0830 (2015).","journal-title":"JAMA Oncol."},{"key":"1211_CR51","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/annonc\/mdz047","volume":"30","author":"R Barroso-Sousa","year":"2019","unstructured":"Barroso-Sousa, R. et al. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Ann. Oncol. 30, 575\u2013581 https:\/\/doi.org\/10.1093\/annonc\/mdz047 (2019).","journal-title":"Ann. Oncol."},{"key":"1211_CR52","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40\u201350 https:\/\/doi.org\/10.1016\/S1470-2045(17)30904-X (2018).","journal-title":"Lancet Oncol."},{"key":"1211_CR53","doi-asserted-by":"publisher","first-page":"104109","DOI":"10.1016\/j.esmoop.2024.104109","volume":"10","author":"L Angelats","year":"2025","unstructured":"Angelats, L. et al. Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer. ESMO Open 10, 104109 https:\/\/doi.org\/10.1016\/j.esmoop.2024.104109 (2025).","journal-title":"ESMO Open"},{"key":"1211_CR54","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1158\/1078-0432.Ccr-25-3123","volume":"32","author":"E Sanfeliu","year":"2026","unstructured":"Sanfeliu, E. et al. Associations of the HER2DX genomic test with biological and pathologic features in HER2-positive breast cancer. Clin. Cancer Res. 32, 570\u2013580 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-3123 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR55","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/S1470-2045(20)30450-2","volume":"21","author":"A Prat","year":"2020","unstructured":"Prat, A. et al. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncol. 21, 1455\u20131464 https:\/\/doi.org\/10.1016\/S1470-2045(20)30450-2 (2020).","journal-title":"Lancet Oncol."},{"key":"1211_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42635-2","volume":"14","author":"M Rediti","year":"2023","unstructured":"Rediti, M. et al. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nat. Commun. 14, 7053 https:\/\/doi.org\/10.1038\/s41467-023-42635-2 (2023).","journal-title":"Nat. Commun."},{"key":"1211_CR57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S1470-2045(16)30631-3","volume":"18","author":"SJ Luen","year":"2017","unstructured":"Luen, S. J. et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 18, 52\u201362 https:\/\/doi.org\/10.1016\/S1470-2045(16)30631-3 (2017).","journal-title":"Lancet Oncol."},{"key":"1211_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2021.08.007","volume":"60","author":"P Mand\u00f3","year":"2021","unstructured":"Mand\u00f3, P., Rivero, S. G., Rizzo, M. M., Pinkasz, M. & Levy, E. M. Targeting ADCC: a different approach to HER2 breast cancer in the immunotherapy era. Breast 60, 15\u201325 https:\/\/doi.org\/10.1016\/j.breast.2021.08.007 (2021).","journal-title":"Breast"},{"key":"1211_CR59","doi-asserted-by":"publisher","first-page":"RF3-04","DOI":"10.1158\/1557-3265.Sabcs24-rf3-04","volume":"31","author":"V Valero","year":"2025","unstructured":"Valero, V. et al. Abstract RF3-04: NRG-BR004: a randomized, double-blind, phase III trial of taxane\/trastuzumab\/pertuzumab with atezolizumab or placebo in first-line HER2-positive metastatic breast cancer. Clin. Cancer Res. 31, RF3-04 https:\/\/doi.org\/10.1158\/1557-3265.Sabcs24-rf3-04 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR60","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/jco.21.02772","volume":"40","author":"J Huober","year":"2022","unstructured":"Huober, J. et al. Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: primary results of the randomized phase III IMpassion050 trial. J. Clin. Oncol. 40, 2946\u20132956 https:\/\/doi.org\/10.1200\/jco.21.02772 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR61","doi-asserted-by":"publisher","first-page":"RF3-05","DOI":"10.1158\/1557-3265.Sabcs24-rf3-05","volume":"31","author":"H McArthur","year":"2025","unstructured":"McArthur, H. et al. Abstract RF3-05: a phase 2 study of neoadjuvant HER2-targeted therapy +\/- immunotherapy with pembrolizumab (neoHIP). Clin. Cancer Res. 31, RF3-05 https:\/\/doi.org\/10.1158\/1557-3265.Sabcs24-rf3-05 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR62","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1093\/jnci\/92.24.1991","volume":"92","author":"S Paik","year":"2000","unstructured":"Paik, S. et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: national surgical adjuvant breast and bowel project protocol B-15. J. Natl Cancer Inst. 92, 1991\u20131998 https:\/\/doi.org\/10.1093\/jnci\/92.24.1991 (2000).","journal-title":"J. Natl Cancer Inst."},{"key":"1211_CR63","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/s0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron, D. et al. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet 389, 1195\u20131205 https:\/\/doi.org\/10.1016\/s0140-6736(16)32616-2 (2017).","journal-title":"Lancet"},{"key":"1211_CR64","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","volume":"22","author":"R Bradley","year":"2021","unstructured":"Bradley, R. et al. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 22, 1139\u20131150 https:\/\/doi.org\/10.1016\/S1470-2045(21)00288-6 (2021).","journal-title":"Lancet Oncol."},{"key":"1211_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105112","author":"S Loibl","year":"2025","unstructured":"Loibl, S. et al. LBA1 Adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or Pla + T + CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: final analysis at 11.3 years\u2019 median follow-up. ESMO Open https:\/\/doi.org\/10.1016\/j.esmoop.2025.105112 (2025).","journal-title":"ESMO Open"},{"key":"1211_CR66","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/coc.0000000000000563","volume":"42","author":"JP Leone","year":"2019","unstructured":"Leone, J. P., Leone, J., Zwenger, A. O., Vallejo, C. T. & Leone, B. A. Prognostic significance of tumor subtypes in women with breast cancer according to stage: a population-based study. Am. J. Clin. Oncol. 42, 588\u2013595 https:\/\/doi.org\/10.1097\/coc.0000000000000563 (2019).","journal-title":"Am. J. Clin. Oncol."},{"key":"1211_CR67","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.1200\/jco.2009.22.0962","volume":"27","author":"G Curigliano","year":"2009","unstructured":"Curigliano, G. et al. Clinical relevance of HER2 overexpression\/amplification in patients with small tumor size and node-negative breast cancer. J. Clin. Oncol. 27, 5693\u20135699 https:\/\/doi.org\/10.1200\/jco.2009.22.0962 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR68","doi-asserted-by":"publisher","first-page":"5700","DOI":"10.1200\/jco.2009.23.2025","volume":"27","author":"AM Gonzalez-Angulo","year":"2009","unstructured":"Gonzalez-Angulo, A. M. et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J. Clin. Oncol. 27, 5700\u20135706 https:\/\/doi.org\/10.1200\/jco.2009.23.2025 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR69","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/cncr.34750","volume":"129","author":"A Weiss","year":"2023","unstructured":"Weiss, A. et al. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: results from two international cohorts. Cancer 129, 1836\u20131845 https:\/\/doi.org\/10.1002\/cncr.34750 (2023).","journal-title":"Cancer"},{"key":"1211_CR70","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1056\/NEJMoa2406070","volume":"392","author":"CE Geyer","year":"2025","unstructured":"Geyer, C. E. et al. Survival with trastuzumab emtansine in residual HER2-positive breast cancer. N. Engl. J. Med. 392, 249\u2013257 https:\/\/doi.org\/10.1056\/NEJMoa2406070 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR71","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","volume":"24","author":"SM Tolaney","year":"2023","unstructured":"Tolaney, S. M. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 24, 273\u2013285 https:\/\/doi.org\/10.1016\/S1470-2045(23)00051-7 (2023).","journal-title":"Lancet Oncol."},{"key":"1211_CR72","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1200\/jco.23.02170","volume":"42","author":"P Tarantino","year":"2024","unstructured":"Tarantino, P. et al. Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I human epidermal growth factor receptor 2\u2013positive breast cancer: 5-year results and correlative analyses from ATEMPT. J. Clin. Oncol. 42, 3652\u20133665 https:\/\/doi.org\/10.1200\/jco.23.02170 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR73","unstructured":"NCCN clinical practice guidelines in oncology. breast cancer. Version 2.2026. NCCN (accessed 20 March 2026)."},{"key":"1211_CR74","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1200\/JCO.2026.44.16_suppl.508","volume":"44","author":"R Wang","year":"2026","unstructured":"Wang, R. et al. Adjuvant capecitabine and trastuzumab for stage IA HER2-positive breast cancer (IRIS-A): a phase II clinical trial. J. Clin. Oncol. 44, 508\u2013508 https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.508 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR75","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"EG Committee","year":"2024","unstructured":"Committee, E. G. et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 35, 159\u2013182 https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016 (2024).","journal-title":"Ann. Oncol."},{"key":"1211_CR76","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1001\/jamaoncol.2024.3679","volume":"10","author":"P Tarantino","year":"2024","unstructured":"Tarantino, P., Hortobagyi, G., Tolaney, S. M. & Mittendorf, E. A. Heterogeneity of residual disease after neoadjuvant systemic therapy in breast cancer: a review. JAMA Oncol. 10, 1578\u20131584 https:\/\/doi.org\/10.1001\/jamaoncol.2024.3679 (2024).","journal-title":"JAMA Oncol."},{"key":"1211_CR77","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni, L. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 25\u201332 https:\/\/doi.org\/10.1016\/S1470-2045(11)70336-9 (2012).","journal-title":"Lancet Oncol."},{"key":"1211_CR78","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"GV Minckwitz","year":"2017","unstructured":"Minckwitz, G. V. et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N. Engl. J. Med. 377, 122\u2013131 https:\/\/doi.org\/10.1056\/NEJMoa1703643 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR79","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/jco.21.01059","volume":"39","author":"P Tarantino","year":"2021","unstructured":"Tarantino, P., Tolaney, S. M., Harbeck, N., Cortes, J. & Curigliano, G. Anthracyclines for human epidermal growth factor receptor 2-positive breast cancer: are we ready to let them go? J. Clin. Oncol. 39, 3541\u20133545 https:\/\/doi.org\/10.1200\/jco.21.01059 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00342-5","volume":"7","author":"SA Hurvitz","year":"2021","unstructured":"Hurvitz, S. A. et al. A careful reassessment of anthracycline use in curable breast cancer. npj Breast Cancer 7, 134 https:\/\/doi.org\/10.1038\/s41523-021-00342-5 (2021).","journal-title":"npj Breast Cancer"},{"key":"1211_CR81","doi-asserted-by":"publisher","first-page":"S5-04","DOI":"10.1158\/1538-7445.Sabcs15-s5-04","volume":"76","author":"D Slamon","year":"2016","unstructured":"Slamon, D. et al. Abstract S5-04: ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC\u2192T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC\u2192TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Cancer Res. 76, S5-04 https:\/\/doi.org\/10.1158\/1538-7445.Sabcs15-s5-04 (2016).","journal-title":"Cancer Res."},{"key":"1211_CR82","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","volume":"19","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz, S. A. et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 19, 115\u2013126 https:\/\/doi.org\/10.1016\/S1470-2045(17)30716-7 (2018).","journal-title":"Lancet Oncol."},{"key":"1211_CR83","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst, M. S. et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 19, 1630\u20131640 https:\/\/doi.org\/10.1016\/S1470-2045(18)30570-9 (2018).","journal-title":"Lancet Oncol."},{"key":"1211_CR84","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","volume":"7","author":"A van der Voort","year":"2021","unstructured":"van der Voort, A. et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol. 7, 978\u2013984 https:\/\/doi.org\/10.1001\/jamaoncol.2021.1371 (2021).","journal-title":"JAMA Oncol."},{"key":"1211_CR85","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1200\/JCO.2025.43.16_suppl.501","volume":"43","author":"NM Tung","year":"2025","unstructured":"Tung, N. M. et al. Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II\/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the EA1181\/CompassHER2 pCR trial [abstract]. J. Clin. Oncol. 43, 501 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR86","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-02255","volume":"20","author":"N Tung","year":"2026","unstructured":"Tung, N. et al. Pathologic complete response (pCR) rate and predictors of response to taxane, trastuzumab, and pertuzumab in HER2-positive breast cancer: secondary analyses of EA1181\/CompassHER2 pCR. J. Clin. Oncol. 20, JCO-25-02255 https:\/\/doi.org\/10.1200\/jco-25-02255 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR87","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2026.2023","author":"P Tarantino","year":"2026","unstructured":"Tarantino, P. et al. Neoadjuvant paclitaxel, trastuzumab, and pertuzumab for stage II to III, ERBB2-positive breast cancer: a secondary analysis of the DAPHNe Trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2026.2023 (2026).","journal-title":"JAMA Oncol."},{"key":"1211_CR88","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(22)00159-0","volume":"23","author":"U Nitz","year":"2022","unstructured":"Nitz, U. et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+\/HR\u2212): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 23, 625\u2013635 https:\/\/doi.org\/10.1016\/S1470-2045(22)00159-0 (2022).","journal-title":"Lancet Oncol."},{"key":"1211_CR89","doi-asserted-by":"publisher","first-page":"P3-11-03","DOI":"10.1158\/1557-3265.Sabcs24-p3-11-03","volume":"31","author":"E Agostinetto","year":"2025","unstructured":"Agostinetto, E. et al. Abstract P3-11-03: de-escalation of chemotherapy in patients with HER2-positive, hormone receptor negative, node-negative early breast cancer: primary results of the phase II DECRESCENDO trial. Clin. Cancer Res. 31, P3-11-03 https:\/\/doi.org\/10.1158\/1557-3265.Sabcs24-p3-11-03 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR90","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1200\/jco-25-02855","volume":"44","author":"P Tarantino","year":"2026","unstructured":"Tarantino, P. Rise and fall of neoadjuvant carboplatin for human epidermal growth factor receptor 2\u2013positive breast cancer. J. Clin. Oncol. 44, 1561\u20131566 https:\/\/doi.org\/10.1200\/jco-25-02855 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR91","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1200\/jco-25-02176","volume":"44","author":"H-F Gao","year":"2026","unstructured":"Gao, H.-F. et al. Neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in human epidermal growth factor receptor 2\u2013positive breast cancer: the randomized noninferiority phase III neoCARHP trial. J. Clin. Oncol. 44, 1587\u20131596 https:\/\/doi.org\/10.1200\/jco-25-02176 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR92","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(24)00581-3","volume":"26","author":"XC Chen","year":"2025","unstructured":"Chen, X. C. et al. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. Lancet Oncol. 26, 27\u201336 https:\/\/doi.org\/10.1016\/S1470-2045(24)00581-3 (2025).","journal-title":"Lancet Oncol."},{"key":"1211_CR93","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/s1470-2045(14)70160-3","volume":"15","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz, G. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 15, 747\u2013756 https:\/\/doi.org\/10.1016\/s1470-2045(14)70160-3 (2014).","journal-title":"Lancet Oncol."},{"key":"1211_CR94","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","volume":"29","author":"S Loibl","year":"2018","unstructured":"Loibl, S. et al. Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response \u2014 final results from GeparSixto. Ann. Oncol. 29, 2341\u20132347 https:\/\/doi.org\/10.1093\/annonc\/mdy460 (2018).","journal-title":"Ann. Oncol."},{"key":"1211_CR95","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1200\/jco.2010.28.6450","volume":"29","author":"V Valero","year":"2011","unstructured":"Valero, V. et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J. Clin. Oncol. 29, 149\u2013156 https:\/\/doi.org\/10.1200\/jco.2010.28.6450 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR96","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jamaoncol.2025.0001","volume":"11","author":"LL Michel","year":"2025","unstructured":"Michel, L. L. et al. Efficacy of hand cooling and compression in preventing taxane-induced neuropathy: the POLAR randomized clinical trial. JAMA Oncol. 11, 408\u2013415 https:\/\/doi.org\/10.1001\/jamaoncol.2025.0001 (2025).","journal-title":"JAMA Oncol."},{"key":"1211_CR97","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","volume":"18","author":"A Llombart-Cussac","year":"2017","unstructured":"Llombart-Cussac, A. et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 18, 545\u2013554 https:\/\/doi.org\/10.1016\/S1470-2045(17)30021-9 (2017).","journal-title":"Lancet Oncol."},{"key":"1211_CR98","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1016\/j.annonc.2022.03.111","volume":"33","author":"T Pascual","year":"2022","unstructured":"Pascual, T. et al. 95P PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study. Ann. Oncol. 33, S168 https:\/\/doi.org\/10.1016\/j.annonc.2022.03.111 (2022).","journal-title":"Ann. Oncol."},{"key":"1211_CR99","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","volume":"22","author":"JM P\u00e9rez-Garc\u00eda","year":"2021","unstructured":"P\u00e9rez-Garc\u00eda, J. M. et al. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 22, 858\u2013871 https:\/\/doi.org\/10.1016\/S1470-2045(21)00122-4 (2021).","journal-title":"Lancet Oncol."},{"key":"1211_CR100","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","volume":"403","author":"JM P\u00e9rez-Garc\u00eda","year":"2024","unstructured":"P\u00e9rez-Garc\u00eda, J. M. et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet 403, 1649\u20131659 https:\/\/doi.org\/10.1016\/S0140-6736(24)00054-0 (2024).","journal-title":"Lancet"},{"key":"1211_CR101","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.annonc.2026.01.013","volume":"37","author":"L Garrigos","year":"2026","unstructured":"Garrigos, L. et al. A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study. Ann. Oncol. 37, 837\u2013848 https:\/\/doi.org\/10.1016\/j.annonc.2026.01.013 (2026).","journal-title":"Ann. Oncol."},{"key":"1211_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.107171","author":"FM Louis","year":"2026","unstructured":"Louis, F. M. et al. 217RO Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in HER2+ early breast cancer: the TRAIN-4 study. ESMO Open https:\/\/doi.org\/10.1016\/j.esmoop.2026.107171 (2026).","journal-title":"ESMO Open"},{"key":"1211_CR103","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/s0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164\u2013172 https:\/\/doi.org\/10.1016\/s0140-6736(13)62422-8 (2014).","journal-title":"Lancet"},{"key":"1211_CR104","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1200\/JCO.22.02241","volume":"41","author":"MT van Mackelenbergh","year":"2023","unstructured":"van Mackelenbergh, M. T. et al. Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer. J. Clin. Oncol. 41, 2998\u20133008 https:\/\/doi.org\/10.1200\/JCO.22.02241 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR105","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1200\/JCO.2026.44.16_suppl.535","volume":"44","author":"P Tarantino","year":"2026","unstructured":"Tarantino, P., Sanglier, T., Hernandez, E. G., Janicijevic, T. K. & Abbass, I. Adjuvant antibody-drug conjugate (ADC) eligibility and corresponding prognosis in HER2+ early breast cancer (eBC): a US-based real-world comparison of KATHERINE and DESTINY-Breast05 populations. J. Clin. Oncol. 44, 535\u2013535 https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.535 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR106","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","volume":"21","author":"A Chan","year":"2021","unstructured":"Chan, A. et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin. Breast Cancer 21, 80\u201391 https:\/\/doi.org\/10.1016\/j.clbc.2020.09.014 (2021).","journal-title":"Clin. Breast Cancer"},{"key":"1211_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000533657","volume":"19","author":"N Harbeck","year":"2024","unstructured":"Harbeck, N. et al. Neratinib as extended adjuvant treatment of HER2-positive\/HR-positive early breast cancer patients in Germany, Austria, and Switzerland: interim results of the prospective, observational ELEANOR study. Breast Care 19, 1\u20139 https:\/\/doi.org\/10.1159\/000533657 (2024).","journal-title":"Breast Care"},{"key":"1211_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104894","author":"PA Fasching","year":"2025","unstructured":"Fasching, P. A. et al. 322P Human epidermal growth factor receptor 2 (HER2)-directed therapies administered after trastuzumab deruxtecan (T-DXd) remain effective in patients (pts) with metastatic breast cancer (mBC): exploratory analysis from DESTINY-Breast02 and -03. ESMO Open https:\/\/doi.org\/10.1016\/j.esmoop.2025.104894 (2025).","journal-title":"ESMO Open"},{"key":"1211_CR109","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1200\/JCO.2026.44.16_suppl.1021","volume":"44","author":"YH Park","year":"2026","unstructured":"Park, Y. H. et al. A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P). J. Clin. Oncol. 44, 1021 https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.1021 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR110","doi-asserted-by":"publisher","first-page":"539","DOI":"10.6004\/jnccn.2025.7080","volume":"23","author":"SJ Bae","year":"2025","unstructured":"Bae, S. J. et al. Ovarian function suppression in HR-positive, HER2-positive breast cancer: an exploratory analysis of the HERA trial. J. Natl Compr. Canc. Netw. 23, 539\u2013547 https:\/\/doi.org\/10.6004\/jnccn.2025.7080 (2025).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"1211_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00509-2","volume":"9","author":"MV Dieci","year":"2023","unstructured":"Dieci, M. V. et al. Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive\/HER2-positive BC: analysis from the phase III randomized ShortHER trial. npj Breast Cancer 9, 6 https:\/\/doi.org\/10.1038\/s41523-023-00509-2 (2023).","journal-title":"npj Breast Cancer"},{"key":"1211_CR112","doi-asserted-by":"publisher","first-page":"GS1-03","DOI":"10.1158\/1557-3265.Sabcs25-gs1-03","volume":"32","author":"M Lambertini","year":"2026","unstructured":"Lambertini, M. et al. Abstract GS1-03: adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive\/HER2-positive early breast cancer: an exploratory analysis from the ALTTO (BIG 2-06) trial. Clin. Cancer Res. 32, GS1-03 https:\/\/doi.org\/10.1158\/1557-3265.Sabcs25-gs1-03 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR113","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","volume":"18","author":"M Martin","year":"2017","unstructured":"Martin, M. et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1688\u20131700 https:\/\/doi.org\/10.1016\/S1470-2045(17)30717-9 (2017).","journal-title":"Lancet Oncol."},{"key":"1211_CR114","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2023.02.002","volume":"184","author":"FA Holmes","year":"2023","unstructured":"Holmes, F. A. et al. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): a randomised, double-blind, placebo-controlled, phase 3 trial. Eur. J. Cancer 184, 48\u201359 https:\/\/doi.org\/10.1016\/j.ejca.2023.02.002 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1211_CR115","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 21, 519\u2013530 https:\/\/doi.org\/10.1016\/s1470-2045(19)30863-0 (2020).","journal-title":"Lancet Oncol."},{"key":"1211_CR116","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat. Med. 30, 2208\u20132215 https:\/\/doi.org\/10.1038\/s41591-024-03021-7 (2024).","journal-title":"Nat. Med."},{"key":"1211_CR117","doi-asserted-by":"publisher","first-page":"Cd006242","DOI":"10.1002\/14651858.CD006242.pub2","volume":"2014","author":"S Balduzzi","year":"2014","unstructured":"Balduzzi, S. et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst. Rev. 2014, Cd006242 https:\/\/doi.org\/10.1002\/14651858.CD006242.pub2 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1211_CR118","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/jco.2011.37.4207","volume":"30","author":"J Cortes","year":"2012","unstructured":"Cortes, J. et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 30, 1594\u20131600 https:\/\/doi.org\/10.1200\/jco.2011.37.4207 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR119","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1093\/annonc\/mdt274","volume":"24","author":"J Cortes","year":"2013","unstructured":"Cortes, J. et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann. Oncol. 24, 2630\u20132635 https:\/\/doi.org\/10.1093\/annonc\/mdt274 (2013).","journal-title":"Ann. Oncol."},{"key":"1211_CR120","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.annonc.2021.06.024","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles, D. et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann. Oncol. 32, 1245\u20131255 https:\/\/doi.org\/10.1016\/j.annonc.2021.06.024 (2021).","journal-title":"Ann. Oncol."},{"key":"1211_CR121","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/jco-24-01888","volume":"43","author":"T Yamashita","year":"2025","unstructured":"Yamashita, T. et al. Trastuzumab-pertuzumab plus eribulin or taxane as first-line chemotherapy for human epidermal growth factor 2-positive locally advanced\/metastatic breast cancer: the randomized noninferiority phase III EMERALD trial. J. Clin. Oncol. 43, 1302\u20131313 https:\/\/doi.org\/10.1200\/jco-24-01888 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR122","doi-asserted-by":"publisher","first-page":"S403","DOI":"10.1016\/j.annonc.2025.08.960","volume":"36","author":"S Saji","year":"2025","unstructured":"Saji, S. et al. 537P Final survival outcomes of eribulin mesylate in combination with trastuzumab and pertuzumab as first-line chemotherapy for HER2-positive, locally advanced or metastatic breast cancer: results of the randomized, non-inferiority phase 3 JBCRG-M06\/EMERALD study. Ann. Oncol. 36, S403 https:\/\/doi.org\/10.1016\/j.annonc.2025.08.960 (2025).","journal-title":"Ann. Oncol."},{"key":"1211_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0773-6","volume":"18","author":"EA Perez","year":"2016","unstructured":"Perez, E. A. et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET cohort 1 final results. Breast Cancer Res. 18, 126 https:\/\/doi.org\/10.1186\/s13058-016-0773-6 (2016).","journal-title":"Breast Cancer Res."},{"key":"1211_CR124","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jama.2016.20939","volume":"317","author":"J Nangia","year":"2017","unstructured":"Nangia, J. et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. J. Am. Med. Assoc. 317, 596\u2013605 https:\/\/doi.org\/10.1001\/jama.2016.20939 (2017).","journal-title":"J. Am. Med. Assoc."},{"key":"1211_CR125","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/s1470-2045(18)30083-4","volume":"19","author":"H Wildiers","year":"2018","unstructured":"Wildiers, H. et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force\/Breast Cancer Group. Lancet Oncol. 19, 323\u2013336 https:\/\/doi.org\/10.1016\/s1470-2045(18)30083-4 (2018).","journal-title":"Lancet Oncol."},{"key":"1211_CR126","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1158\/1078-0432.Ccr-22-1092","volume":"29","author":"G Arpino","year":"2023","unstructured":"Arpino, G. et al. Pertuzumab, trastuzumab, and an aromatase inhibitor for HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer: PERTAIN final analysis. Clin. Cancer Res. 29, 1468\u20131476 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-1092 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR127","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.Ccr-23-1209","volume":"30","author":"SM Tolaney","year":"2024","unstructured":"Tolaney, S. M. et al. Overall survival and exploratory biomarker analyses of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus chemotherapy in HR+, HER2+ metastatic breast cancer patients. Clin. Cancer Res. 30, 39\u201349 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-1209 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR128","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1158\/1078-0432.Ccr-20-0844","volume":"26","author":"E Ciruelos","year":"2020","unstructured":"Ciruelos, E. et al. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial. Clin. Cancer Res. 26, 5820\u20135829 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0844 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR129","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy, R. K. et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N. Engl. J. Med. 382, 597\u2013609 https:\/\/doi.org\/10.1056\/NEJMoa1914609 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR130","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s1470-2045(20)30702-6","volume":"22","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 351\u2013360 https:\/\/doi.org\/10.1016\/s1470-2045(20)30702-6 (2021).","journal-title":"Lancet Oncol."},{"key":"1211_CR131","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO-25-02600","volume":"44","author":"V Dieras","year":"2025","unstructured":"Dieras, V. et al. HER2CLIMB-05: a phase III study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2+ metastatic breast cancer. J. Clin. Oncol. 44, 1597\u20131607 https:\/\/doi.org\/10.1200\/JCO-25-02600 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR132","doi-asserted-by":"publisher","first-page":"e087259","DOI":"10.1136\/bmj-2025-087259","volume":"392","author":"F Ma","year":"2026","unstructured":"Ma, F. et al. Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial. Br. Med. J. 392, e087259 https:\/\/doi.org\/10.1136\/bmj-2025-087259 (2026).","journal-title":"Br. Med. J."},{"key":"1211_CR133","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/s1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger, M. et al. Characterisation and classification of oligometastatic disease: a european society for radiotherapy and oncology and european organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 21, e18\u2013e28 https:\/\/doi.org\/10.1016\/s1470-2045(19)30718-1 (2020).","journal-title":"Lancet Oncol."},{"key":"1211_CR134","doi-asserted-by":"publisher","first-page":"P4-12-03","DOI":"10.1158\/1538-7445.Sabcs19-p4-12-03","volume":"80","author":"JG Bazan","year":"2020","unstructured":"Bazan, J. G., Holbrook, A., Jhawar, S. & White, J. R. Abstract P4-12-03: patterns of progression in metastatic breast cancer: does oligoprogression exist? Cancer Res. 80, P4-12-03 https:\/\/doi.org\/10.1158\/1538-7445.Sabcs19-p4-12-03 (2020).","journal-title":"Cancer Res."},{"key":"1211_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115164","author":"M Milano","year":"2025","unstructured":"Milano, M. et al. Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer. Eur. J. Cancer https:\/\/doi.org\/10.1016\/j.ejca.2024.115164 (2025).","journal-title":"Eur. J. Cancer"},{"key":"1211_CR136","doi-asserted-by":"publisher","first-page":"104667","DOI":"10.1016\/j.breast.2025.104667","volume":"85","author":"N Bianco","year":"2026","unstructured":"Bianco, N. et al. Metastasis-directed thermal ablation in patients with metastatic breast cancer and visceral oligoprogression or oligopersistence: a cohort study. Breast 85, 104667 https:\/\/doi.org\/10.1016\/j.breast.2025.104667 (2026).","journal-title":"Breast"},{"key":"1211_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105920","author":"C Valenza","year":"2025","unstructured":"Valenza, C. et al. Breast surgery and systemic treatment continuation for patients with de novo metastatic breast cancer and locoregional oligoprogression: a cohort study. ESMO Open https:\/\/doi.org\/10.1016\/j.esmoop.2025.105920 (2025).","journal-title":"ESMO Open"},{"key":"1211_CR138","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","volume":"18","author":"V Di\u00e9ras","year":"2017","unstructured":"Di\u00e9ras, V. et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 18, 732\u2013742 https:\/\/doi.org\/10.1016\/S1470-2045(17)30312-1 (2017).","journal-title":"Lancet Oncol."},{"key":"1211_CR139","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","volume":"35","author":"EA Perez","year":"2017","unstructured":"Perez, E. A. et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J. Clin. Oncol. 35, 141\u2013148 https:\/\/doi.org\/10.1200\/JCO.2016.67.4887 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR140","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5687-0","volume":"19","author":"EA Perez","year":"2019","unstructured":"Perez, E. A. et al. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine \u00b1 pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC Cancer 19, 517 https:\/\/doi.org\/10.1186\/s12885-019-5687-0 (2019).","journal-title":"BMC Cancer"},{"key":"1211_CR141","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.trecan.2023.11.001","volume":"10","author":"C Valenza","year":"2024","unstructured":"Valenza, C. et al. Targeting HER2 heterogeneity in breast and gastrointestinal cancers. Trends Cancer 10, 113\u2013123 https:\/\/doi.org\/10.1016\/j.trecan.2023.11.001 (2024).","journal-title":"Trends Cancer"},{"key":"1211_CR142","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andre","year":"2023","unstructured":"Andre, F. et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401, 1773\u20131785 https:\/\/doi.org\/10.1016\/S0140-6736(23)00725-0 (2023).","journal-title":"Lancet"},{"key":"1211_CR143","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med. 386, 1143\u20131154 https:\/\/doi.org\/10.1056\/NEJMoa2115022 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR144","doi-asserted-by":"publisher","first-page":"RF6-07","DOI":"10.1158\/1557-3265.Sabcs25-rf6-07","volume":"32","author":"M Rimawi","year":"2026","unstructured":"Rimawi, M. et al. Abstract RF6-07: trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with HER2-positive (HER2+) advanced\/metastatic breast cancer (a\/mBC): patient-reported outcomes (PROs) from the DESTINY-Breast09 study. Clin. Cancer Res. 32, RF6-07 https:\/\/doi.org\/10.1158\/1557-3265.Sabcs25-rf6-07 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR145","doi-asserted-by":"publisher","first-page":"P5-03-11","DOI":"10.1158\/1557-3265.Sabcs24-p5-03-11","volume":"31","author":"J Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s, J. et al. Abstract P5-03-11: DEMETHER: a single-arm phase II trial to evaluate the efficacy & safety of subcutaneous pertuzumab & trastuzumab maintenance after induction treatment w\/ trastuzumab deruxtecan (T-DXd) for previously untreated HER2-positive advanced breast cancer. Clin. Cancer Res. 31, P5-03-11 https:\/\/doi.org\/10.1158\/1557-3265.Sabcs24-p5-03-11 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR146","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1200\/jco-25-02942","volume":"44","author":"C Valenza","year":"2026","unstructured":"Valenza, C., Nixon, N. A., Cheung, W. Y. & Tolaney, S. M. Bridging the gap: advancing first-line therapy for patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 44, 1571\u20131574 https:\/\/doi.org\/10.1200\/jco-25-02942 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR147","doi-asserted-by":"publisher","first-page":"104125","DOI":"10.1016\/j.esmoop.2024.104125","volume":"10","author":"E Blondeaux","year":"2025","unstructured":"Blondeaux, E. et al. Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world. ESMO Open 10, 104125 https:\/\/doi.org\/10.1016\/j.esmoop.2024.104125 (2025).","journal-title":"ESMO Open"},{"key":"1211_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2026.104883","volume":"89","author":"K Nozawa","year":"2026","unstructured":"Nozawa, K. et al. Trastuzumab deruxtecan rechallenge in HER2-positive metastatic breast cancer: EN-SEMBLE. Breast 89, 104883 https:\/\/doi.org\/10.1016\/j.breast.2026.104883 (2026).","journal-title":"Breast"},{"key":"1211_CR149","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/jco.2008.19.6618","volume":"27","author":"G von Minckwitz","year":"2009","unstructured":"von Minckwitz, G. et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26\/breast international group 03-05 study. J. Clin. Oncol. 27, 1999\u20132006 https:\/\/doi.org\/10.1200\/jco.2008.19.6618 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR150","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","volume":"33","author":"G Curigliano","year":"2022","unstructured":"Curigliano, G. et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann. Oncol. 33, 321\u2013329 https:\/\/doi.org\/10.1016\/j.annonc.2021.12.005 (2022).","journal-title":"Ann. Oncol."},{"key":"1211_CR151","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1093\/jnci\/djaf220","volume":"117","author":"P Tarantino","year":"2025","unstructured":"Tarantino, P. et al. Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer. J. Natl Cancer Inst. 117, 2327\u20132335 https:\/\/doi.org\/10.1093\/jnci\/djaf220 (2025).","journal-title":"J. Natl Cancer Inst."},{"key":"1211_CR152","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1056\/NEJMoa071167","volume":"357","author":"DF Hayes","year":"2007","unstructured":"Hayes, D. F. et al. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 357, 1496\u20131506 https:\/\/doi.org\/10.1056\/NEJMoa071167 (2007).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR153","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/jco-24-01673","volume":"43","author":"Y Yamamoto","year":"2025","unstructured":"Yamamoto, Y. et al. Pertuzumab retreatment for human epidermal growth factor receptor 2\u2013positive locally advanced\/metastatic breast cancer (PRECIOUS Study): final overall survival analysis. J. Clin. Oncol. 43, 1631\u20131637 https:\/\/doi.org\/10.1200\/jco-24-01673 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR154","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1200\/jco.20.00147","volume":"38","author":"C Saura","year":"2020","unstructured":"Saura, C. et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial. J. Clin. Oncol. 38, 3138\u20133149 https:\/\/doi.org\/10.1200\/jco.20.00147 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR155","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer, C. E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733\u20132743 https:\/\/doi.org\/10.1056\/NEJMoa064320 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR156","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1200\/jco.21.02937","volume":"41","author":"HS Rugo","year":"2023","unstructured":"Rugo, H. S. et al. Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial. J. Clin. Oncol. 41, 198\u2013205 https:\/\/doi.org\/10.1200\/jco.21.02937 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR157","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","volume":"7","author":"HS Rugo","year":"2021","unstructured":"Rugo, H. S. et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 7, 573\u2013584 https:\/\/doi.org\/10.1001\/jamaoncol.2020.7932 (2021).","journal-title":"JAMA Oncol."},{"key":"1211_CR158","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/s1470-2045(20)30536-2","volume":"22","author":"AR Tan","year":"2021","unstructured":"Tan, A. R. et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 22, 85\u201397 https:\/\/doi.org\/10.1016\/s1470-2045(20)30536-2 (2021).","journal-title":"Lancet Oncol."},{"key":"1211_CR159","doi-asserted-by":"publisher","first-page":"PO2-20-01","DOI":"10.1158\/1538-7445.Sabcs23-po2-20-01","volume":"84","author":"H Parsons","year":"2024","unstructured":"Parsons, H. et al. Abstract PO2-20-01: the STOP-HER2 Trial: a phase 2 study of stopping trastuzumab - outcomes in patients with HER2+ metastatic breast cancer (TBCRC 062). Cancer Res. 84, PO2-20-01 https:\/\/doi.org\/10.1158\/1538-7445.Sabcs23-po2-20-01 (2024).","journal-title":"Cancer Res."},{"key":"1211_CR160","doi-asserted-by":"publisher","first-page":"PS5-11","DOI":"10.1158\/1557-3265.Sabcs25-ps5-11","volume":"32","author":"S Morganti","year":"2026","unstructured":"Morganti, S. et al. Abstract PS5-11: ultrasensitive ctDNA tracking predicts exceptional response in HER2+ metastatic breast cancer. Clin. Cancer Res. 32, PS5-11 https:\/\/doi.org\/10.1158\/1557-3265.Sabcs25-ps5-11 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR161","doi-asserted-by":"publisher","first-page":"PO2-04-01","DOI":"10.1158\/1538-7445.Sabcs23-po2-04-01","volume":"84","author":"S Morganti","year":"2024","unstructured":"Morganti, S. et al. Abstract PO2-04-01: predictors of exceptional response to first line HER2-targeted therapy for metastatic breast cancer. Cancer Res. 84, PO2-04-01 https:\/\/doi.org\/10.1158\/1538-7445.Sabcs23-po2-04-01 (2024).","journal-title":"Cancer Res."},{"key":"1211_CR162","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11864-024-01286-1","volume":"26","author":"T Grinda","year":"2025","unstructured":"Grinda, T., Aizer, A. A., Lin, N. U. & Sammons, S. L. Central nervous system metastases in breast cancer. Curr. Treat. Options Oncol. 26, 14\u201335 https:\/\/doi.org\/10.1007\/s11864-024-01286-1 (2025).","journal-title":"Curr. Treat. Options Oncol."},{"key":"1211_CR163","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/jnci\/djaf048","volume":"117","author":"SL Sammons","year":"2025","unstructured":"Sammons, S. L. et al. Prevalence by therapy line and incidence of breast cancer brain metastases in 18075 patients. J. Natl Cancer Inst. 117, 1565\u20131572 https:\/\/doi.org\/10.1093\/jnci\/djaf048 (2025).","journal-title":"J. Natl Cancer Inst."},{"key":"1211_CR164","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/jco.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum, M. A. et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J. Clin. Oncol. 40, 492\u2013516 https:\/\/doi.org\/10.1200\/jco.21.02314 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR165","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2026.0076","author":"AA Aizer","year":"2026","unstructured":"Aizer, A. A. et al. Treatment for brain metastases with stereotactic radiation vs hippocampal-avoidance whole brain radiation: a randomized clinical trial. J. Am. Med. Assoc. https:\/\/doi.org\/10.1001\/jama.2026.0076 (2026).","journal-title":"J. Am. Med. Assoc."},{"key":"1211_CR166","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/s1470-2045(17)30441-2","volume":"18","author":"PD Brown","year":"2017","unstructured":"Brown, P. D. et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 18, 1049\u20131060 https:\/\/doi.org\/10.1016\/s1470-2045(17)30441-2 (2017).","journal-title":"Lancet Oncol."},{"key":"1211_CR167","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/jamaoncol.2025.3007","volume":"11","author":"JT Yang","year":"2025","unstructured":"Yang, J. T. et al. Proton craniospinal irradiation for patients with leptomeningeal metastasis: a randomized clinical trial. JAMA Oncol. 11, 1293\u20131301 https:\/\/doi.org\/10.1001\/jamaoncol.2025.3007 (2025).","journal-title":"JAMA Oncol."},{"key":"1211_CR168","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck, N. et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat. Med. 30, 3717\u20133727 https:\/\/doi.org\/10.1038\/s41591-024-03261-7 (2024).","journal-title":"Nat. Med."},{"key":"1211_CR169","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin, N. U. et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 9, 197\u2013205 https:\/\/doi.org\/10.1001\/jamaoncol.2022.5610 (2023).","journal-title":"JAMA Oncol."},{"key":"1211_CR170","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jamaoncol.2023.4492","volume":"9","author":"ES Lebow","year":"2023","unstructured":"Lebow, E. S. et al. Symptomatic necrosis with antibody-drug conjugates and concurrent stereotactic radiotherapy for brain metastases. JAMA Oncol. 9, 1729\u20131733 https:\/\/doi.org\/10.1001\/jamaoncol.2023.4492 (2023).","journal-title":"JAMA Oncol."},{"key":"1211_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2026.104691","volume":"85","author":"L Visani","year":"2026","unstructured":"Visani, L. et al. Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort. Breast 85, 104691 https:\/\/doi.org\/10.1016\/j.breast.2026.104691 (2026).","journal-title":"Breast"},{"key":"1211_CR172","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clbc.2026.05.010","volume":"26","author":"S Modi","year":"2026","unstructured":"Modi, S. et al. Tucatinib in combination with trastuzumab deruxtecan in patients with previously treated HER2+ unresectable locally advanced or metastatic breast cancer: an open-label phase 2 study. Clin. Breast Cancer 26, 21\u201330 https:\/\/doi.org\/10.1016\/j.clbc.2026.05.010 (2026).","journal-title":"Clin. Breast Cancer"},{"key":"1211_CR173","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","volume":"31","author":"F Montemurro","year":"2020","unstructured":"Montemurro, F. et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann. Oncol. 31, 1350\u20131358 https:\/\/doi.org\/10.1016\/j.annonc.2020.06.020 (2020).","journal-title":"Ann. Oncol."},{"key":"1211_CR174","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.annonc.2024.07.245","volume":"35","author":"RA Freedman","year":"2024","unstructured":"Freedman, R. A. et al. Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022. Ann. Oncol. 35, 993\u20131002 https:\/\/doi.org\/10.1016\/j.annonc.2024.07.245 (2024).","journal-title":"Ann. Oncol."},{"key":"1211_CR175","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00587-2","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin, N. U. et al. Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data. npj Breast Cancer 9, 94 https:\/\/doi.org\/10.1038\/s41523-023-00587-2 (2023).","journal-title":"npj Breast Cancer"},{"key":"1211_CR176","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","volume":"14","author":"T Bachelot","year":"2013","unstructured":"Bachelot, T. et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 14, 64\u201371 https:\/\/doi.org\/10.1016\/S1470-2045(12)70432-1 (2013).","journal-title":"Lancet Oncol."},{"key":"1211_CR177","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1200\/jco.18.01511","volume":"37","author":"RA Freedman","year":"2019","unstructured":"Freedman, R. A. et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J. Clin. Oncol. 37, 1081\u20131089 https:\/\/doi.org\/10.1200\/jco.18.01511 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR178","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/jamaoncol.2023.5791","volume":"10","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive advanced breast cancer and brain metastases: a nonrandomized phase 2 trial. JAMA Oncol. 10, 335\u2013341 https:\/\/doi.org\/10.1001\/jamaoncol.2023.5791 (2024).","journal-title":"JAMA Oncol."},{"key":"1211_CR179","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s12282-024-01614-1","volume":"31","author":"T Nakayama","year":"2024","unstructured":"Nakayama, T. et al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and\/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM). Breast Cancer 31, 1167\u20131175 https:\/\/doi.org\/10.1007\/s12282-024-01614-1 (2024).","journal-title":"Breast Cancer"},{"key":"1211_CR180","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00519-0","volume":"9","author":"L Alder","year":"2023","unstructured":"Alder, L. et al. Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. npj Breast Cancer 9, 19 https:\/\/doi.org\/10.1038\/s41523-023-00519-0 (2023).","journal-title":"npj Breast Cancer"},{"key":"1211_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-026-01120-7","author":"RK Murthy","year":"2026","unstructured":"Murthy, R. K. et al. Tucatinib\u2013trastuzumab\u2013capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results. Nat. Cancer https:\/\/doi.org\/10.1038\/s43018-026-01120-7 (2026).","journal-title":"Nat. Cancer"},{"key":"1211_CR182","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/noac195","volume":"25","author":"PU Kumthekar","year":"2023","unstructured":"Kumthekar, P. U. et al. A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics. NeuroOncology 25, 557\u2013565 https:\/\/doi.org\/10.1093\/neuonc\/noac195 (2023).","journal-title":"NeuroOncology"},{"key":"1211_CR183","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2018.02.032","volume":"95","author":"C Bonneau","year":"2018","unstructured":"Bonneau, C. et al. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur. J. Cancer 95, 75\u201384 https:\/\/doi.org\/10.1016\/j.ejca.2018.02.032 (2018).","journal-title":"Eur. J. Cancer"},{"key":"1211_CR184","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/jco.22.00520","volume":"40","author":"N Ramakrishna","year":"2022","unstructured":"Ramakrishna, N. et al. Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update. J. Clin. Oncol. 40, 2636\u20132655 https:\/\/doi.org\/10.1200\/jco.22.00520 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103756","volume":"76","author":"F Cardoso","year":"2024","unstructured":"Cardoso, F. et al. 6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast 76, 103756 https:\/\/doi.org\/10.1016\/j.breast.2024.103756 (2024).","journal-title":"Breast"},{"key":"1211_CR186","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari, A. et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 32, 1475\u20131495 https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019 (2021).","journal-title":"Ann. Oncol."},{"key":"1211_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.05.707","author":"E de Azambuja","year":"2026","unstructured":"de Azambuja, E. et al. Metastatic breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2026.05.707 (2026).","journal-title":"Ann. Oncol."},{"key":"1211_CR188","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1158\/1078-0432.Ccr-25-3557","volume":"32","author":"G Griguolo","year":"2026","unstructured":"Griguolo, G. et al. Proactive brain screening using contrast-enhanced brain CT scans in HER2+ metastatic breast cancer. Clin. Cancer Res. 32, 1790\u20131798 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-3557 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR189","doi-asserted-by":"publisher","first-page":"106892","DOI":"10.1016\/j.esmoop.2026.106892","volume":"11","author":"GM Kim","year":"2026","unstructured":"Kim, G. M. et al. A prospective study for brain metastasis imaging screening in patients with advanced HER2-positive or triple-negative breast cancer. ESMO Open 11, 106892 https:\/\/doi.org\/10.1016\/j.esmoop.2026.106892 (2026).","journal-title":"ESMO Open"},{"key":"1211_CR190","doi-asserted-by":"publisher","first-page":"e2020303","DOI":"10.1001\/jamanetworkopen.2020.20303","volume":"3","author":"X Kong","year":"2020","unstructured":"Kong, X. et al. Variation in breast cancer subtype incidence and distribution by race\/ethnicity in the united states from 2010 to 2015. JAMA Netw. Open 3, e2020303 https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.20303 (2020).","journal-title":"JAMA Netw. Open"},{"key":"1211_CR191","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00341","author":"JW Chen","year":"2022","unstructured":"Chen, J. W. et al. Comparison of PIK3CA mutation prevalence in breast cancer across predicted ancestry populations. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/po.22.00341 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"1211_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell, C. A. et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 7, 100554 https:\/\/doi.org\/10.1016\/j.esmoop.2022.100554 (2022).","journal-title":"ESMO Open"},{"key":"1211_CR193","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1200\/JCO.2025.43.16_suppl.1036","volume":"43","author":"Z Shah","year":"2025","unstructured":"Shah, Z. et al. Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody\u2013drug conjugates: a TriNetX real-world evidence study. J. Clin. Oncol. 43, 1036\u20131036 https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.1036 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR194","doi-asserted-by":"publisher","first-page":"e235834","DOI":"10.1001\/jamanetworkopen.2023.5834","volume":"6","author":"S Shubeck","year":"2023","unstructured":"Shubeck, S., Zhao, F., Howard, F. M., Olopade, O. I. & Huo, D. Response to treatment, racial and ethnic disparity, and survival in patients with breast cancer undergoing neoadjuvant chemotherapy in the US. JAMA Netw. Open 6, e235834 https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.5834 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1211_CR195","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01587-z","volume":"25","author":"SL de Haas","year":"2023","unstructured":"de Haas, S. L. et al. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine\u2009+\u2009pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). Breast Cancer Res. 25, 2 https:\/\/doi.org\/10.1186\/s13058-022-01587-z (2023).","journal-title":"Breast Cancer Res."},{"key":"1211_CR196","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.molonc.2015.09.002","volume":"10","author":"P Nuciforo","year":"2016","unstructured":"Nuciforo, P. et al. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol. Oncol. 10, 138\u2013147 https:\/\/doi.org\/10.1016\/j.molonc.2015.09.002 (2016).","journal-title":"Mol. Oncol."},{"key":"1211_CR197","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0543-x","volume":"17","author":"DA Yardley","year":"2015","unstructured":"Yardley, D. A. et al. Quantitative measurement of HER2 expression in breast cancers: comparison with \u2018real-world\u2019 routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival. Breast Cancer Res. 17, 41 https:\/\/doi.org\/10.1186\/s13058-015-0543-x (2015).","journal-title":"Breast Cancer Res."},{"key":"1211_CR198","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/JCO.19.00882","volume":"37","author":"SA Hurvitz","year":"2019","unstructured":"Hurvitz, S. A. et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE Study. J. Clin. Oncol. 37, 2206\u20132216 https:\/\/doi.org\/10.1200\/JCO.19.00882 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR199","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-020-05524-6","volume":"180","author":"N Masuda","year":"2020","unstructured":"Masuda, N. et al. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel\u2009+\u2009carboplatin\u2009+\u2009trastuzumab\u2009+\u2009pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Breast Cancer Res. Treat. 180, 135\u2013146 https:\/\/doi.org\/10.1007\/s10549-020-05524-6 (2020).","journal-title":"Breast Cancer Res. Treat."},{"key":"1211_CR200","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10549-024-07333-7","volume":"207","author":"T Takano","year":"2024","unstructured":"Takano, T. et al. Long-term outcomes of neoadjuvant trastuzumab emtansine\u2009+\u2009pertuzumab (T-DM1\u2009+\u2009P) and docetaxel\u2009+\u2009carboplatin\u2009+\u2009trastuzumab\u2009+\u2009pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast Cancer Res. Treat. 207, 33\u201348 https:\/\/doi.org\/10.1007\/s10549-024-07333-7 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"1211_CR201","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1200\/JCO.19.00443","volume":"37","author":"S Chumsri","year":"2019","unstructured":"Chumsri, S. et al. Incidence of late relapses in patients with HER2-positive breast cancer receiving adjuvant trastuzumab: combined analysis of NCCTG N9831 (Alliance) and NRG oncology\/NSABP B-31. J. Clin. Oncol. 37, 3425\u20133435 https:\/\/doi.org\/10.1200\/JCO.19.00443 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR202","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s10549-011-1412-7","volume":"132","author":"S Gl\u00fcck","year":"2012","unstructured":"Gl\u00fcck, S. et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine \u00b1 trastuzumab. Breast Cancer Res. Treat. 132, 781\u2013791 https:\/\/doi.org\/10.1007\/s10549-011-1412-7 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"1211_CR203","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/annonc\/mdw262","volume":"27","author":"MV Dieci","year":"2016","unstructured":"Dieci, M. V. et al. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Ann. Oncol. 27, 1867\u20131873 https:\/\/doi.org\/10.1093\/annonc\/mdw262 (2016).","journal-title":"Ann. Oncol."},{"key":"1211_CR204","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103801","volume":"75","author":"A Prat","year":"2022","unstructured":"Prat, A. et al. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. eBioMedicine 75, 103801 https:\/\/doi.org\/10.1016\/j.ebiom.2021.103801 (2022).","journal-title":"eBioMedicine"},{"key":"1211_CR205","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1002\/1878-0261.13141","volume":"16","author":"T Triulzi","year":"2022","unstructured":"Triulzi, T. et al. The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. Mol. Oncol. 16, 2355\u20132366 https:\/\/doi.org\/10.1002\/1878-0261.13141 (2022).","journal-title":"Mol. Oncol."},{"key":"1211_CR206","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/s1470-2045(25)00276-1","volume":"26","author":"G Villacampa","year":"2025","unstructured":"Villacampa, G. et al. HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis. Lancet Oncol. 26, 1100\u20131112 https:\/\/doi.org\/10.1016\/s1470-2045(25)00276-1 (2025).","journal-title":"Lancet Oncol."},{"key":"1211_CR207","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.annonc.2023.05.012","volume":"34","author":"G Villacampa","year":"2023","unstructured":"Villacampa, G. et al. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer. Ann. Oncol. 34, 783\u2013795 https:\/\/doi.org\/10.1016\/j.annonc.2023.05.012 (2023).","journal-title":"Ann. Oncol."},{"key":"1211_CR208","doi-asserted-by":"publisher","first-page":"104702","DOI":"10.1016\/j.esmoop.2025.104702","volume":"10","author":"T Pascual","year":"2025","unstructured":"Pascual, T. et al. 149TiP DEFINITIVE TRIAL: diagnostic HER2DX-guided treatment for patIents wIth early-stage HER2-positive breast cancer. ESMO Open 10, 104702 https:\/\/doi.org\/10.1016\/j.esmoop.2025.104702 (2025).","journal-title":"ESMO Open"},{"key":"1211_CR209","doi-asserted-by":"publisher","first-page":"PS4-01-07","DOI":"10.1158\/1557-3265.Sabcs25-ps4-01-07","volume":"32","author":"MG Rodriguez","year":"2026","unstructured":"Rodriguez, M. G. et al. Abstract PS4-01-07: prospective validation of HER2DX in early HER2+ breast cancer: operational feasibility of centralized genomic screening in the DEFINITIVE trial. Real-time insights from the first 80 screened patients. Clin. Cancer Res. 32, PS4-01-07 https:\/\/doi.org\/10.1158\/1557-3265.Sabcs25-ps4-01-07 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65432-5","volume":"16","author":"MJM Magbanua","year":"2025","unstructured":"Magbanua, M. J. M. et al. Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. Nat. Commun. 16, 9945 https:\/\/doi.org\/10.1038\/s41467-025-65432-5 (2025).","journal-title":"Nat. Commun."},{"key":"1211_CR211","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02934","author":"NB Hunter","year":"2026","unstructured":"Hunter, N. B. et al. The pathologic response evaluation and detection in circulating tumor-DNA study: ultrasensitive circulating tumor-DNA assessment of breast cancer minimal residual disease. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO-25-02934 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR212","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.2024.42.16_suppl.588","volume":"42","author":"A Waks","year":"2024","unstructured":"Waks, A. et al. Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel\/trastuzumab\/pertuzumab (THP) in the DAPHNe trial. J. Clin. Oncol. 42, 588 https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.588 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR213","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1470-2045(25)00707-7","volume":"27","author":"FM Louis","year":"2026","unstructured":"Louis, F. M. et al. MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study. Lancet Oncol. 27, 349\u2013360 https:\/\/doi.org\/10.1016\/S1470-2045(25)00707-7 (2026).","journal-title":"Lancet Oncol."},{"key":"1211_CR214","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(24)00104-9","volume":"25","author":"A van der Voort","year":"2024","unstructured":"van der Voort, A. et al. MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II\u2013III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study. Lancet Oncol. 25, 603\u2013613 https:\/\/doi.org\/10.1016\/S1470-2045(24)00104-9 (2024).","journal-title":"Lancet Oncol."},{"key":"1211_CR215","doi-asserted-by":"publisher","first-page":"GS1-06","DOI":"10.1158\/1557-3265.Sabcs25-gs1-06","volume":"32","author":"A Llombart-Cussac","year":"2026","unstructured":"Llombart-Cussac, A. et al. Abstract GS1-06: circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2+) Early Breast Cancer (EBC): translational analysis of PHERGain neoadjuvant tailored treatment study. Clin. Cancer Res. 32, GS1-06 https:\/\/doi.org\/10.1158\/1557-3265.Sabcs25-gs1-06 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR216","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(25)00097-X","volume":"26","author":"S Kuemmel","year":"2025","unstructured":"Kuemmel, S. et al. Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial. Lancet Oncol. 26, 629\u2013640 https:\/\/doi.org\/10.1016\/S1470-2045(25)00097-X (2025).","journal-title":"Lancet Oncol."},{"key":"1211_CR217","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.Ccr-24-3472","volume":"31","author":"MJ Elliott","year":"2025","unstructured":"Elliott, M. J. et al. Ultrasensitive detection and monitoring of circulating tumor DNA using structural variants in early-stage breast cancer. Clin. Cancer Res. 31, 1520\u20131532 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-3472 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR218","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/jnci\/djab057","volume":"114","author":"N Chic","year":"2022","unstructured":"Chic, N. et al. Tumor cellularity and infiltrating lymphocytes as a survival surrogate in HER2-positive breast cancer. J. Natl Cancer Inst. 114, 467\u2013470 https:\/\/doi.org\/10.1093\/jnci\/djab057 (2022).","journal-title":"J. Natl Cancer Inst."},{"key":"1211_CR219","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/annonc\/mdx647","volume":"29","author":"P Nuciforo","year":"2018","unstructured":"Nuciforo, P. et al. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann. Oncol. 29, 170\u2013177 https:\/\/doi.org\/10.1093\/annonc\/mdx647 (2018).","journal-title":"Ann. Oncol."},{"key":"1211_CR220","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s43018-021-00190-z","volume":"2","author":"KL McNamara","year":"2021","unstructured":"McNamara, K. L. et al. Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nat. Cancer 2, 400\u2013413 https:\/\/doi.org\/10.1038\/s43018-021-00190-z (2021).","journal-title":"Nat. Cancer"},{"key":"1211_CR221","doi-asserted-by":"publisher","first-page":"PS2-08-10","DOI":"10.1158\/1557-3265.Sabcs25-ps2-08-10","volume":"32","author":"E Segui","year":"2026","unstructured":"Segui, E. et al. Abstract PS2-08-10: peripheral immune profiling during neoadjuvant HER2-targeted therapy in HER2-positive (HER2+) early breast cancer (EBC): mass cytometry (CyTOF) analysis from the MARGOT trial. Clin. Cancer Res. 32, PS2-08-10 https:\/\/doi.org\/10.1158\/1557-3265.Sabcs25-ps2-08-10 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR222","doi-asserted-by":"publisher","first-page":"102923","DOI":"10.1016\/j.ctrv.2025.102923","volume":"135","author":"S Nakatani","year":"2025","unstructured":"Nakatani, S., Hayashi, T., Yamamoto, K. & Maeda, H. Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: a systematic review and meta-analysis. Cancer Treat. Rev. 135, 102923 https:\/\/doi.org\/10.1016\/j.ctrv.2025.102923 (2025).","journal-title":"Cancer Treat. Rev."},{"key":"1211_CR223","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113920","volume":"201","author":"P Tarantino","year":"2024","unstructured":"Tarantino, P. et al. Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer. Eur. J. Cancer 201, 113920 https:\/\/doi.org\/10.1016\/j.ejca.2024.113920 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1211_CR224","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1158\/2767-9764.Crc-24-0234","volume":"6","author":"PH Lin","year":"2026","unstructured":"Lin, P. H. et al. ctDNA detected after neoadjuvant therapy for her2-positive breast cancer is associated with inferior outcomes and may inform adjuvant therapy. Cancer Res. Commun. 6, 105\u2013114 https:\/\/doi.org\/10.1158\/2767-9764.Crc-24-0234 (2026).","journal-title":"Cancer Res. Commun."},{"key":"1211_CR225","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/1078-0432.Ccr-25-2882","volume":"32","author":"E Ciruelos","year":"2026","unstructured":"Ciruelos, E. et al. Palbociclib, trastuzumab, and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomized phase II, SOLTI-1303 PATRICIA Trial. Clin. Cancer Res. 32, 674\u2013683 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-2882 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR226","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00753-8","volume":"11","author":"R S\u00e1nchez-Bayona","year":"2025","unstructured":"S\u00e1nchez-Bayona, R. et al. HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab. npj Breast Cancer 11, 37 https:\/\/doi.org\/10.1038\/s41523-025-00753-8 (2025).","journal-title":"npj Breast Cancer"},{"key":"1211_CR227","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-026-00909-0","volume":"12","author":"M Kubeczko","year":"2026","unstructured":"Kubeczko, M. et al. Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane. npj Breast Cancer 12, 43 https:\/\/doi.org\/10.1038\/s41523-026-00909-0 (2026).","journal-title":"npj Breast Cancer"},{"key":"1211_CR228","doi-asserted-by":"publisher","first-page":"PS4-06","DOI":"10.1158\/1557-3265.Sabcs24-ps4-06","volume":"31","author":"J Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s, J. et al. Abstract PS4-06: HER2DX ERBB2 mRNA score in first-line metastatic HER2-positive breast cancer treated with docetaxel, trastuzumab and pertuzumab: correlative analysis from CLEOPATRA phase III trial. Clin. Cancer Res. 31, PS4-06 https:\/\/doi.org\/10.1158\/1557-3265.Sabcs24-ps4-06 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR229","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/jnci\/djac227","volume":"115","author":"F Braso-Maristany","year":"2023","unstructured":"Braso-Maristany, F. et al. HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. J. Natl Cancer Inst. 115, 332\u2013336 https:\/\/doi.org\/10.1093\/jnci\/djac227 (2023).","journal-title":"J. Natl Cancer Inst."},{"key":"1211_CR230","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-026-01365-6","author":"P Tarantino","year":"2026","unstructured":"Tarantino, P. et al. Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer. npj Precis. Oncol. https:\/\/doi.org\/10.1038\/s41698-026-01365-6 (2026).","journal-title":"npj Precis. Oncol."},{"key":"1211_CR231","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00868-y","volume":"12","author":"GW Sledge","year":"2025","unstructured":"Sledge, G. W. et al. Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling. npj Breast Cancer 12, 1 https:\/\/doi.org\/10.1038\/s41523-025-00868-y (2025).","journal-title":"npj Breast Cancer"},{"key":"1211_CR232","doi-asserted-by":"publisher","first-page":"S1563","DOI":"10.1016\/j.annonc.2025.09.028","volume":"36","author":"S Loibl","year":"2025","unstructured":"Loibl, S. et al. LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced\/metastatic breast cancer (a\/mBC): additional analyses of DESTINY-Breast09 in key subgroups of interest. Ann. Oncol. 36, S1563\u2013S1564 https:\/\/doi.org\/10.1016\/j.annonc.2025.09.028 (2025).","journal-title":"Ann. Oncol."},{"key":"1211_CR233","doi-asserted-by":"publisher","first-page":"104983","DOI":"10.1016\/j.esmoop.2025.104983","volume":"10","author":"T De La Motte Rouge","year":"2025","unstructured":"De La Motte Rouge, T. et al. 412TiP HEROES: de-escalation of medical therapies in HER2-positive metastatic breast cancer in long-term persistent response and minimal residual disease undetectable in circulating tumor DNA. ESMO Open 10, 104983 https:\/\/doi.org\/10.1016\/j.esmoop.2025.104983 (2025).","journal-title":"ESMO Open"},{"key":"1211_CR234","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00432-023-05519-y","volume":"150","author":"F Gao","year":"2024","unstructured":"Gao, F. et al. Molecular probes targeting HER2 PET\/CT and their application in advanced breast cancer. J. Cancer Res. Clin. Oncol. 150, 118 https:\/\/doi.org\/10.1007\/s00432-023-05519-y (2024).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1211_CR235","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae188","author":"X Gui","year":"2025","unstructured":"Gui, X., Liang, X., Guo, X., Yang, Z. & Song, G. Impact of HER2-targeted PET\/CT imaging in patients with breast cancer and therapeutic response monitoring. Oncologist https:\/\/doi.org\/10.1093\/oncolo\/oyae188 (2025).","journal-title":"Oncologist"},{"key":"1211_CR236","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/annonc\/mdv577","volume":"27","author":"G Gebhart","year":"2016","unstructured":"Gebhart, G. et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann. Oncol. 27, 619\u2013624 https:\/\/doi.org\/10.1093\/annonc\/mdv577 (2016).","journal-title":"Ann. Oncol."},{"key":"1211_CR237","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37029-3","volume":"14","author":"NE Weisser","year":"2023","unstructured":"Weisser, N. E. et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat. Commun. 14, 1394 https:\/\/doi.org\/10.1038\/s41467-023-37029-3 (2023).","journal-title":"Nat. Commun."},{"key":"1211_CR238","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-025-02163-3","volume":"85","author":"SJ Keam","year":"2025","unstructured":"Keam, S. J. Zanidatamab: first approval. Drugs 85, 707\u2013714 https:\/\/doi.org\/10.1007\/s40265-025-02163-3 (2025).","journal-title":"Drugs"},{"key":"1211_CR239","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJMoa2517729","volume":"394","author":"K Shitara","year":"2026","unstructured":"Shitara, K. et al. Zanidatamab with and without tislelizumab in HER2-positive gastroesophageal cancer. N. Engl. J. Med. 394, 2002\u20132014 https:\/\/doi.org\/10.1056\/NEJMoa2517729 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR240","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105852","volume":"10","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib\/II study. ESMO Open 10, 105852 https:\/\/doi.org\/10.1016\/j.esmoop.2025.105852 (2025).","journal-title":"ESMO Open"},{"key":"1211_CR241","doi-asserted-by":"publisher","first-page":"P2-13-07","DOI":"10.1158\/1538-7445.Sabcs21-p2-13-07","volume":"82","author":"PL Bedard","year":"2022","unstructured":"Bedard, P. L. et al. Abstract P2-13-07: zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): results from a phase 1 study. Cancer Res. 82, P2-13-07 https:\/\/doi.org\/10.1158\/1538-7445.Sabcs21-p2-13-07 (2022).","journal-title":"Cancer Res."},{"key":"1211_CR242","doi-asserted-by":"publisher","first-page":"CT256","DOI":"10.1158\/1538-7445.Am2025-ct256","volume":"85","author":"SM Tolaney","year":"2025","unstructured":"Tolaney, S. M. et al. Abstract CT256: EmpowHER-303: a phase 3 study of zanidatamab vs trastuzumab with physician\u2019s choice of chemotherapy in patients with HER2+ metastatic breast cancer whose disease progressed on trastuzumab deruxtecan. Cancer Res. 85, CT256 https:\/\/doi.org\/10.1158\/1538-7445.Am2025-ct256 (2025).","journal-title":"Cancer Res."},{"key":"1211_CR243","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cac2.12662","volume":"45","author":"J Ma","year":"2025","unstructured":"Ma, J. et al. Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial. Cancer Commun. 45, 476\u2013485 https:\/\/doi.org\/10.1002\/cac2.12662 (2025).","journal-title":"Cancer Commun."},{"key":"1211_CR244","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2026.3329","author":"J Li","year":"2026","unstructured":"Li, J. et al. Neoadjuvant anbenitamab and HB1801 in ERBB2-positive breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2026.3329 (2026).","journal-title":"JAMA Oncol."},{"key":"1211_CR245","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1200\/JCO.2025.43.16_suppl.1028","volume":"43","author":"Y Du","year":"2025","unstructured":"Du, Y. et al. JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: a pooled analysis of early-phase studies. J. Clin. Oncol. 43, 1028 https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.1028 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR246","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.2025.43.16_suppl.3003","volume":"43","author":"R-H Xu","year":"2025","unstructured":"Xu, R.-H. et al. Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody\u2013drug conjugate, in patients with advanced solid tumors: preliminary data from the first-in-human phase 1 trial. J. Clin. Oncol. 43, 3003\u20133003 https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3003 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR247","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/jco-25-01153","volume":"44","author":"J-J Li","year":"2026","unstructured":"Li, J.-J. et al. Efficacy and safety of neoadjuvant TQB2102 in locally advanced or early human epidermal growth factor receptor 2\u2013positive breast cancer: a randomized, open-label, multicenter, phase II trial. J. Clin. Oncol. 44, 20\u201330 https:\/\/doi.org\/10.1200\/jco-25-01153 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR248","unstructured":"Mullard, A. Dual-payload ADCs move into first oncology clinical trials. Nature https:\/\/www.nature.com\/articles\/d41573-025-00121-y (8 July 2025)."},{"key":"1211_CR249","doi-asserted-by":"publisher","first-page":"CT204","DOI":"10.1158\/1538-7445.Am2025-ct204","volume":"85","author":"S Modi","year":"2025","unstructured":"Modi, S. et al. Abstract CT204: phase 1a\/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC). Cancer Res. 85, CT204 https:\/\/doi.org\/10.1158\/1538-7445.Am2025-ct204 (2025).","journal-title":"Cancer Res."},{"key":"1211_CR250","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/1078-0432.Ccr-24-1552","volume":"31","author":"S Piha-Paul","year":"2025","unstructured":"Piha-Paul, S. et al. A first-in-human study of cinrebafusp alfa, a HER2\/4-1BB bispecific molecule, in patients with HER2-positive advanced solid malignancies. Clin. Cancer Res. 31, 288\u2013298 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1552 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR251","doi-asserted-by":"publisher","first-page":"CT068","DOI":"10.1158\/1538-7445.Am2025-ct068","volume":"85","author":"D-Y Oh","year":"2025","unstructured":"Oh, D.-Y. et al. Abstract CT068: a phase 1\/2, open-label, multicenter, first-in-human study to evaluate the safety, pharmacokinetics, and anti-tumor activity of YH32367 in patients (pts) with HER2+ locally advanced\/metastatic (a\/m) solid tumors. Cancer Res. 85, CT068 https:\/\/doi.org\/10.1158\/1538-7445.Am2025-ct068 (2025).","journal-title":"Cancer Res."},{"key":"1211_CR252","unstructured":"Innovent press release. PR Newswire https:\/\/www.prnewswire.com\/news-releases\/innovent-announces-first-patient-dosed-in-phase-i-clinical-trial-of-anti-pd-1her2-bispecific-antibody-in-china-300965447.html (26 November 2019)."},{"key":"1211_CR253","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1158\/1538-7445.Am2022-4256","volume":"82","author":"C Shang","year":"2022","unstructured":"Shang, C. et al. Abstract 4256: YH012, a novel bispecific anti-HER2 and TROP2 antibody-drug conjugate, exhibits potent antitumor efficacy. Cancer Res. 82, 4256 https:\/\/doi.org\/10.1158\/1538-7445.Am2022-4256 (2022).","journal-title":"Cancer Res."},{"key":"1211_CR254","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/s41401-024-01279-8","volume":"45","author":"HF Zong","year":"2024","unstructured":"Zong, H. F. et al. A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer. Acta Pharmacol. Sin. 45, 1727\u20131739 https:\/\/doi.org\/10.1038\/s41401-024-01279-8 (2024).","journal-title":"Acta Pharmacol. Sin."},{"key":"1211_CR255","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s10637-025-01507-w","volume":"43","author":"H Huang","year":"2025","unstructured":"Huang, H., Zhou, Y., Shang, C., Zhang, Y. & Shen, Y. A novel anti-HER2\/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs. Invest. New Drugs 43, 262\u2013275 https:\/\/doi.org\/10.1007\/s10637-025-01507-w (2025).","journal-title":"Invest. New Drugs"},{"key":"1211_CR256","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100361","volume":"7","author":"J Tobias","year":"2022","unstructured":"Tobias, J., Garner-Spitzer, E., Drini\u0107, M. & Wiedermann, U. Vaccination against Her-2\/neu, with focus on peptide-based vaccines. ESMO Open 7, 100361 https:\/\/doi.org\/10.1016\/j.esmoop.2021.100361 (2022).","journal-title":"ESMO Open"},{"key":"1211_CR257","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1158\/1078-0432.CCR-18-2867","volume":"25","author":"EA Mittendorf","year":"2019","unstructured":"Mittendorf, E. A. et al. Efficacy and safety analysis of nelipepimut-s vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial. Clin. Cancer Res. 25, 4248\u20134254 https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2867 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR258","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1158\/1078-0432.Ccr-19-2741","volume":"26","author":"GT Clifton","year":"2020","unstructured":"Clifton, G. T. et al. Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab versus trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer. Clin. Cancer Res. 26, 2515\u20132523 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-2741 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR259","doi-asserted-by":"publisher","first-page":"66192","DOI":"10.18632\/oncotarget.11751","volume":"7","author":"EA Mittendorf","year":"2016","unstructured":"Mittendorf, E. A. et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget 7, 66192\u201366201 https:\/\/doi.org\/10.18632\/oncotarget.11751 (2016).","journal-title":"Oncotarget"},{"key":"1211_CR260","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/annonc\/mdw150","volume":"27","author":"EA Mittendorf","year":"2016","unstructured":"Mittendorf, E. A. et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann. Oncol. 27, 1241\u20131248 https:\/\/doi.org\/10.1093\/annonc\/mdw150 (2016).","journal-title":"Ann. Oncol."},{"key":"1211_CR261","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1200\/jco.2015.33.15_suppl.622","volume":"33","author":"JM Greene","year":"2015","unstructured":"Greene, J. M. et al. Final pre-specified analysis of the phase II trial of the AE37+GM-CSF vaccine in high risk breast cancer patients to prevent recurrence. J. Clin. Oncol. 33, 622 https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.622 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR262","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101575","volume":"5","author":"E Agostinetto","year":"2024","unstructured":"Agostinetto, E., Curigliano, G. & Piccart, M. Emerging treatments in HER2-positive advanced breast cancer: keep raising the bar. Cell Rep. Med. 5, 101575 https:\/\/doi.org\/10.1016\/j.xcrm.2024.101575 (2024).","journal-title":"Cell Rep. Med."},{"key":"1211_CR263","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 https:\/\/doi.org\/10.1038\/mt.2010.24 (2010).","journal-title":"Mol. Ther."},{"key":"1211_CR264","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1385571","volume":"15","author":"Z Niu","year":"2024","unstructured":"Niu, Z. et al. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies. Front. Immunol. 15, 1385571 https:\/\/doi.org\/10.3389\/fimmu.2024.1385571 (2024).","journal-title":"Front. Immunol."},{"key":"1211_CR265","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss, K. A. et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat. Med. 31, 1171\u20131182 https:\/\/doi.org\/10.1038\/s41591-025-03495-z (2025).","journal-title":"Nat. Med."},{"key":"1211_CR266","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/1078-0432.Ccr-20-0768","volume":"26","author":"S-C Lee","year":"2020","unstructured":"Lee, S.-C. et al. Phase I trial of expanded, activated autologous NK-cell infusions with trastuzumab in patients with HER2-positive cancers. Clin. Cancer Res. 26, 4494\u20134502 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0768 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR267","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","volume":"25","author":"A Zippelius","year":"2025","unstructured":"Zippelius, A., Tolaney, S. M., Tarantino, P., Balthasar, J. P. & Thurber, G. M. Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment. Nat. Rev. Cancer 25, 925\u2013944 https:\/\/doi.org\/10.1038\/s41568-025-00869-w (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"1211_CR268","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO.2023.41.16_suppl.2538","volume":"41","author":"BT Li","year":"2023","unstructured":"Li, B. T. et al. A phase 1\/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors. J. Clin. Oncol. 41, 2538 https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.2538 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR269","doi-asserted-by":"publisher","first-page":"S450","DOI":"10.1016\/j.annonc.2021.08.491","volume":"32","author":"SJ Klempner","year":"2021","unstructured":"Klempner, S. J. et al. 209P Interim results of a phase I\/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors. Ann. Oncol. 32, S450 https:\/\/doi.org\/10.1016\/j.annonc.2021.08.491 (2021).","journal-title":"Ann. Oncol."},{"key":"1211_CR270","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-SITC2020.0378","author":"F Janku","year":"2020","unstructured":"Janku, F. et al. 378 A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-SITC2020.0378 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1211_CR271","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-24-2449","volume":"31","author":"RA Bukhalid","year":"2025","unstructured":"Bukhalid, R. A. et al. XMT-2056, a HER2-directed STING agonist antibody\u2013drug conjugate, induces innate antitumor immune responses by acting on cancer cells and tumor-resident immune cells. Clin. Cancer Res. 31, 1766\u20131782 https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2449 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR272","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama, K., Anami, Y., Ha, S. Y. Y. & Yamazaki, C. M. Exploring the next generation of antibody-drug conjugates. Nat. Rev. Clin. Oncol. 21, 203\u2013223 https:\/\/doi.org\/10.1038\/s41571-023-00850-2 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1211_CR273","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni, L. et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 17, 791\u2013800 (2016).","journal-title":"Lancet Oncol."},{"key":"1211_CR274","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1211_CR275","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2021.100285","volume":"28","author":"D Trapani","year":"2021","unstructured":"Trapani, D. et al. The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: the ONCOLLEGE-001 survey. J. Cancer Policy 28, 100285 https:\/\/doi.org\/10.1016\/j.jcpo.2021.100285 (2021).","journal-title":"J. Cancer Policy"},{"key":"1211_CR276","doi-asserted-by":"publisher","DOI":"10.1200\/go.21.00282","author":"V Vanderpuye","year":"2021","unstructured":"Vanderpuye, V., Dadzie, M.-A., Huo, D. & Olopade, O. I. Assessment of breast cancer management in sub-Saharan Africa. JCO Glob. Oncol. https:\/\/doi.org\/10.1200\/go.21.00282 (2021).","journal-title":"JCO Glob. Oncol."},{"key":"1211_CR277","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1634\/theoncologist.2017-0088","volume":"22","author":"J Li","year":"2017","unstructured":"Li, J. et al. Disparities of trastuzumab use in resource-limited or resource-abundant regions and its survival benefit on HER2 positive breast cancer: a real-world study from China. Oncologist 22, 1333\u20131338 https:\/\/doi.org\/10.1634\/theoncologist.2017-0088 (2017).","journal-title":"Oncologist"},{"key":"1211_CR278","unstructured":"US Food & Drug Administration. FDA approves new interchangeable biosimilar to Perjeta. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-new-interchangeable-biosimilar-perjeta? (2025)."},{"key":"1211_CR279","unstructured":"Alphamab Oncology. Alphamab Oncology announces the phase III clinical study of anbenitamab (KN026) combined with HB1801 as neoadjuvant treatment for breast cancer has met the primary endpoint. PR Newswire https:\/\/www.prnewswire.com\/apac\/news-releases\/alphamab-oncology-announces-the-phase-iii-clinical-study-of-anbenitamab-kn026-combined-with-hb1801-as-neoadjuvant-treatment-for-breast-cancer-has-met-the-primary-endpoint-302731464.html (1 April 2026)."},{"key":"1211_CR280","doi-asserted-by":"publisher","first-page":"LBA660","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA660","volume":"44","author":"Z-M Shao","year":"2026","unstructured":"Shao, Z.-M. et al. Anbenitamab plus albumin-bound docetaxel (nab-docetaxel) \u00b1 carboplatin (Cb) versus trastuzumab and pertuzumab plus docetaxel (THP) \u00b1 Cb as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: a randomized, open-label, multicenter, phase 3 trial. J. Clin. Oncol. 44, LBA660 https:\/\/doi.org\/10.1200\/JCO.2026.44.17_suppl.LBA660 (2026).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01211-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01211-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01211-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:02:20Z","timestamp":1791446540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01211-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":280,"alternative-id":["1211"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01211-5","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"16 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.T. reports institutional research funding from AstraZeneca and Ignite Proteomics; speaking roles for AstraZeneca, Daiichi Sankyo, Lilly, Gilead and Roche\/Genentech; and consultant\/advisory roles for AstraZeneca, BioNTech, Daiichi Sankyo, Gilead, Lilly, Menarini\/Stemline, Novartis, Roche\/Genentech and Sanofi. N.U.L. reports institutional research funding from AstraZeneca, Iksuda, Merck, Olema Pharmaceuticals, Pfizer, Roche\/Genentech, Seattle Genetics, Stemline\/Menarini and Zion Pharmaceuticals (as a partner of Roche\/Genentech); honoraria for consultancy from Artera, AstraZeneca, Daiichi Sankyo, Denali Therapeutics, Eisai, Genentech, Olema Pharmaceuticals, Pfizer\/SeaGen, Shorla Oncology and Stemline\/Menarini; royalties from Up to Date as the author of a book (\n                      100 Questions & Answers About Triple Negative Breast Cancer\n                      ); and travel support from AstraZeneca, Daiichi Sankyo and Olema Pharmaceuticals, all outside of the submitted work. A.P. reports grants from and owns shares in Reveal Genomics; personal fees from Roche; grants and personal fees from AstraZeneca, Daiichi Sankyo, Novartis and Ona Therapeutics, outside the submitted work; and has a patent relating to HER2DX and DNADX licensed to Reveal Genomics. G.C. reports consulting fees from AstraZeneca, Bristol Myers Squibb, Daichii Sankyo, Gilead, Lilly, Menarini, Merck, Novartis, Pfizer, SeaGen and Roche; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Dachii Sankyo, Gilead, Lilly, Menarini, Novartis and Pfizer; travel support from Daichii Sankyo; data safety monitoring board and steering committee roles for Roche; and a leadership role at the European Society for Medical Oncology (ESMO, president elect), all outside of the submitted work. A.G.W. reports institutional research funding from Genentech, Gilead, Lilly, Merck, TerSera and Verastem; an educational grant from Pfizer; steering committee and\/or consultancy roles for Jazz Pharmaceuticals, Johnson & Johnson and Pfizer; and educational speaker roles for AstraZeneca and Genentech. S.M.T. reports institutional research funding from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Gilead, Jazz Pharmaceuticals, Lilly, Menarini\/Stemline, Merck, NanoString Technologies, Novartis, Olema Pharmaceuticals, OncoPep, Pfizer, SeaGen and Roche\/Genentech; consulting or advisory roles for Aktis Oncology, Artios Pharma, Arvinas, AstraZeneca, Avenzo Therapeutics, Bayer, BeiGene Therapeutics, Bicycle Therapeutics, BioNTech, Blueprint Medicines, Boehringer Ingelheim, Boundless Bio, Bristol Myers Squibb\/Systimmune, Celcuity, Circle Pharma, Corcept, Cullinan Oncology, Daiichi Sankyo, Denali Therapeutics, Eisai, Lilly, Ellipses Pharma, Gilead, Jazz Pharmaceuticals, Johnson & Johnson\/Ambrx, Launch Therapeutics, Menarini\/Stemline, Merck, Mersana, Novartis, Olema Pharmaceuticals, Ottima Pharma, Pfizer\/SeaGen, Relay Therapeutics, Reveal Genomics, Roche\/Genentech, Samsung Bioepis, Summit Therapeutics, Tempus and Zuellig Pharma; a scientific advisory board role at Valanx BioTech; and travel support from AstraZeneca, Gilead, Jazz Pharmaceuticals, Lilly, Pfizer and Roche, all outside of the submitted work. C.V. and E.S. declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}